Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae-Reference-Cited by-同舟云学术

Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Das Shampa¹^ORCID,Johnson Adam¹,McEntee Laura¹,Farrington Nicola¹,Kirby Adam¹,Unsworth Jennifer¹,Jimenez-Valverde Ana¹,Kolamunnage-Dona Ruwanthi²,Bousquet Justine³,Alibaud Laethitia³,Sable Carole³,Zalacain Magdalena³,Everett Martin³^ORCID,Hope William¹^ORCID

Affiliation:

1. Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom

2. Department of Biostatistics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom

3. Antabio SAS, Labège, France

Abstract

Enterobacteriaceae that produce metallo-β-lactamases (MBLs) are an emerging threat to public health. The metallo-β-lactamase inhibitor (MBLi) ANT2681 inhibits the enzymatic activity of MBLs through interaction with the dinuclear zinc ion cluster present in the active site that is common to these enzymes. ANT2681 is being codeveloped, with meropenem as the partner β-lactam, as a novel combination therapy for infections caused by MBL-producing bacteria. The pharmacokinetics/pharmacodynamics of meropenem-ANT2681 were studied in a murine neutropenic thigh model of NDM-producing Enterobacteriaceae .

Funder

Antabio

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01076-20

Reference30 articles.

1. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

2. World Health Organization. 2017. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. World Health Organization, Geneva, Switzerland.

3. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.

4. Frequency distribution, genotypes and prevalent sequence types of New Delhi metallo-β-lactamase-producing Escherichia coli among clinical isolates around the world: A review

5. Evolution of New Delhi metallo-β-lactamase (NDM) in the clinic: Effects of NDM mutations on stability, zinc affinity, and mono-zinc activity

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- Acinetobacter drug development and AMR preparedness;Antimicrobial Agents and Chemotherapy;2024-08-27

2. In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales;Frontiers in Pharmacology;2024-04-11

3. Recent advances in β-lactamase inhibitor chemotypes and inhibition modes;European Journal of Medicinal Chemistry;2022-11

4. Drug development concerning metallo-β-lactamases in gram-negative bacteria;Frontiers in Microbiology;2022-09-15

5. β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources;Pharmaceuticals;2022-04-13